Current Issue : April-June Volume : 2017 Issue Number : 2 Articles : 3 Articles
The oral mucosa is vascularized whereby absorbed drugs get direct access to the systemic circulation without first pass metabolism. Taking this advantage the present work is to formulate mouth dissolving film of telmisartan for enhanced bioavailability. Drug and excipients studies were conducted using FTIR. Oral films of telmisartan were formulated using HPMC K4M as a film forming agent and propylene glycol as plasticizer. The solvent casting method was used for the preparation of films. Telmisartan oral film was evaluated for folding endurance, thickness, weight variation test, surface pH, content uniformity, dissolving time and in-vitro dissolution. No drugââ?¬â??excipients interaction was observed. The characterization studies depict the purity of drug and all the excipients used in the formulation. The IR spectrum of mixture of telmisartan with all other excipients does not show any changes which indicate its compatibility with other excipients. From the results, it can be concluded that the fast dissolving oral film of telmisartan showed fast disintegration, dissolution of drug in salivary pH. Thus the prepared fast dissolving films of telmisartan could be a better alternative for achieving rapid oral bioavailability....
In recent decades, a variety of pharmaceutical research has been conducted to develop new dosage forms. The desire of improved palatability in orally administered products has prompted the development of numerous formulations with improved performance and acceptability. Mouth dissolving tablets (MDTs) have received ever-increasing demand during the last few decades and the field has become a rapidly growing area in the pharmaceutical industry. The unique property of mouth dissolving tablet is that they are rapidly disintegrating or dissolving and release the drug as soon as they come in contact with saliva, thus obviate the requirement of water during administration. Such formulations provide an opportunity for product line extension in the many elderly persons will have difficulties in taking conventional oral dosage forms (viz., solutions, suspensions, tablets and capsules) because of hand tremors and dysphagia. Swallowing problems also are common in young individuals because of their underdeveloped muscular and nervous systems. Other groups that may experience problems using conventional oral dosage forms include the mentally ill, the developmentally disabled and patients who are uncooperative, on reduced liquid-intake plans, or are nauseated. In some cases such as motion sickness, sudden episodes of allergic attack or coughing and an unavailability of water, swallowing conventional tablets may be difficult. This review also provides the detailed concept of some unique patents, technologies developed and marketed formulations of mouth dissolving tablets (MDTs)....
Polymorphism is the ability of a solid material to exist in more than one form or crystal structure. The complete morphology of a material is described by polymorphism and other variables such as crystal habit, amorphous fraction or crystallographic defects. Polymorphism was done to increase the solubility and stability of drug. A number of methods have been employed for characterizing polymorphs in pharmaceutical solids. Polarizing optical microscopy and thermo microscopy have proven to be useful tools. Experiment was carried out for making different novel polymorphic forms of imatinib and also to check there solubility in different solvent. The six different polymorphic forms are screened for microscopic evaluation by IR spectroscopic. The FTIR studies will show that the standard imatinib will gives peaks at 1560, 981.2, 912.5, 887.8, 664.2, 843.8 and 807.8 cm-1. Apart from standard crystal parameters the IR peaks for polymorphic form P is 1598.7, 784.245, 588.182 and 702.926 cm-1. For polymorphic form Q 2200.38, 1598.7, 1455.95, 1226.96 and 700.034 cm-1. The IR peaks for polymorphic form R will show that 1455.99, 1097, 922.771 and 784.245 cm-1. The IR peak polymorphic from S 1449.24, 1013.41, 1000, 335.99, 700.09 and 529.039 cm-1. The IR peak for polymorphic form T 1082.99, 1000 and 825.384 cm-1 and IR peak for form U 1598.7, 784.245, 702.926 and 588.182 cm-1. In the present research our investigations state that formations of new six polymorphic forms are different than original forms of imatinib....
Loading....